Seelaus Asset Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.65M | Buy |
6,561
+1,007
| +18% | +$217K | 1.16% | 18 |
|
|
2026
Q1 | $1.21M | Buy |
5,554
+547
| +11% | +$121K | 0.87% | 23 |
|
|
2025
Q4 | $1.14M | Sell |
5,007
-100
| -2% | -$22.8K | 0.91% | 24 |
|
|
2025
Q3 | $1.18M | Buy |
5,107
+150
| +3% | +$30.5K | 0.94% | 21 |
|
|
2025
Q2 | $920K | Sell |
4,957
-50
| -1% | -$9.29K | 0.81% | 26 |
|
|
2025
Q1 | $1.05M | Sell |
5,007
-100
| -2% | -$19.4K | 1% | 19 |
|
|
2024
Q4 | $908K | Buy |
5,107
+725
| +17% | +$133K | 0.83% | 24 |
|
|
2024
Q3 | $865K | Buy |
4,382
+70
| +2% | +$13.1K | 0.79% | 30 |
|
|
2024
Q2 | $740K | Buy |
4,312
+1,130
| +36% | +$187K | 0.75% | 32 |
|
|
2024
Q1 | $579K | Hold |
3,182
| – | – | 0.58% | 50 |
|
|
2023
Q4 | $493K | Sell |
3,182
-375
| -11% | -$54.7K | 0.48% | 71 |
|
|
2023
Q3 | $530K | Hold |
3,557
| – | – | 0.6% | 47 |
|
|
2023
Q2 | $479K | Buy |
3,557
+300
| +9% | +$44K | 0.38% | 94 |
|
|
2023
Q1 | $520K | Buy |
3,257
+557
| +21% | +$85.2K | 0.39% | 87 |
|
|
2022
Q4 | $436K | Hold |
2,700
| – | – | 0.33% | 97 |
|
|
2022
Q3 | $362K | Buy |
2,700
+250
| +10% | +$35.9K | 0.29% | 114 |
|
|
2022
Q2 | $375K | Hold |
2,450
| – | – | 0.28% | 115 |
|
|
2022
Q1 | $397K | Sell |
2,450
-650
| -21% | -$94.4K | 0.24% | 130 |
|
|
2021
Q4 | $420K | Hold |
3,100
| – | – | 0.23% | 134 |
|
|
2021
Q3 | $334K | Sell |
3,100
-463
| -13% | -$52.9K | 0.2% | 165 |
|
|
2021
Q2 | $401K | Sell |
3,563
-571
| -14% | -$64.3K | 0.23% | 144 |
|
|
2021
Q1 | $447K | Buy |
4,134
+885
| +27% | +$94.7K | 0.29% | 111 |
|
|
2020
Q4 | $348K | Sell |
3,249
-11,176
| -77% | -$1.07M | 0.25% | 118 |
|
|
2020
Q3 | $1.26M | Sell |
14,425
-2,251
| -13% | -$212K | 1.02% | 31 |
|
|
2020
Q2 | $1.64M | Buy |
16,676
+2,799
| +20% | +$246K | 1.49% | 15 |
|
|
2020
Q1 | $1.06M | Buy |
13,877
+10,827
| +355% | +$922K | 1.25% | 26 |
|
|
2019
Q4 | $270K | Sell |
3,050
-2,119
| -41% | -$176K | 0.22% | 125 |
|
|
2019
Q3 | $391K | Buy |
+5,169
| New | +$354K | 0.34% | 88 |
|
|
2018
Q3 | – | Sell |
-2,300
| Closed | -$213K | – | 179 |
|
|
2018
Q2 | $213K | Hold |
2,300
| – | – | 0.19% | 145 |
|
|
2018
Q1 | $218K | Hold |
2,300
| – | – | 0.19% | 145 |
|
|
2017
Q4 | $222K | Buy |
+2,300
| New | +$217K | 0.19% | 151 |
|
Other funds holding ABBV
ECSS
ATO
Seelaus Asset Management's ABBV Position: Q2 2026 in Review
Seelaus Asset Management increased its AbbVie (ABBV) stake by 18% in Q2 2026, buying an estimated $217K and bringing the position to 6,561 shares worth $1.65M. The position accounts for 1.16% of the portfolio, ranked #18.
Seelaus Asset Management first reported a position in ABBV in Q4 2017 and has held it in 31 quarters since. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Seelaus Asset Management held 6,561 shares of AbbVie worth $1.65M as of Q2 2026.
- Seelaus Asset Management bought 1,007 AbbVie shares in Q2 2026, an estimated $217K.
- AbbVie made up 1.16% of Seelaus Asset Management's portfolio in Q2 2026, its #18 holding.
- Seelaus Asset Management first reported a position in AbbVie in Q4 2017 and has held it in 31 quarters since.
- 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Seelaus Asset Management's 13F filing for Q2 2026, filed 16 Jul 2026.